Mayne Pharma Group Limited (MYX.AX)
AUD 4.85
(-2.02%)
AUD 4.85
(-2.02%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 388.15 Million | 183.58 Million | 157.14 Million | 400.78 Million | 456.98 Million | 525.2 Million |
| Cost of Revenue | 169.62 Million | 156.74 Million | 133.4 Million | 273.76 Million | 316.04 Million | 316.16 Million |
| Gross Profit | 218.52 Million | 26.83 Million | 23.74 Million | 127.01 Million | 140.93 Million | 209.04 Million |
| Operating Expenses | 264.63 Million | 213.28 Million | 145.62 Million | 125.65 Million | 153.06 Million | 179.87 Million |
| Selling, General and Administrative Expenses | 243.07 Million | 197.55 Million | 133.41 Million | 106.74 Million | 131.32 Million | 154.06 Million |
| Research and Development Expenses | 20.23 Million | 15.72 Million | 12.2 Million | 18.91 Million | 21.74 Million | 25.8 Million |
| Other Expenses | 12.06 Million | 12.62 Million | 74.42 Million | 6.37 Million | 15.44 Million | -7.94 Million |
| Cost and Expenses | 434.25 Million | 370.03 Million | 279.02 Million | 399.41 Million | 469.11 Million | 496.03 Million |
| Operating Income | -45.85 Million | -186.44 Million | -121.87 Million | 1.36 Million | -12.13 Million | 29.17 Million |
| Interest Expense | 34.5 Million | 10.45 Million | 11.52 Million | 13.3 Million | 16.77 Million | 18.06 Million |
| Income Tax Expense | -21.46 Million | 47.74 Million | 74.5 Million | -54.8 Million | -40.83 Million | -71.62 Million |
| Earnings before Tax | -190.08 Million | -269.69 Million | -145.58 Million | -263.88 Million | -135.36 Million | -353.71 Million |
| Net Income | -174.23 Million | -316.41 Million | -281.28 Million | -208.42 Million | -92.78 Million | -279.2 Million |
| Earnings Per Share Basic | -2.19 | -3.89 | -3.46 | -2.57 | -1.14 | -3.44 |
| Earnings Per Share Diluted | -2.19 | -3.89 | -3.46 | -2.57 | -1.14 | -3.44 |
| Weighted Average Shares Outstanding | 79.62 Million | 81.24 Million | 81.24 Million | 81.24 Million | 81.24 Million | 81.24 Million |
| Weighted Average Shares Outstanding (Diluted) | 79.62 Million | 81.24 Million | 81.24 Million | 81.24 Million | 81.24 Million | 81.24 Million |
| Gross Margin | 0.56 | 0.15 | 0.15 | 0.32 | 0.31 | 0.40 |
| EBIT Margin | -0.30 | -0.66 | -0.42 | 0.17 | 0.16 | 0.24 |
| Profit Margin | -0.45 | -1.72 | -1.79 | -0.52 | -0.20 | -0.53 |
| EBITDA | -116.92 Million | -193.8 Million | -78.88 Million | -182.39 Million | -34.03 Million | -241.15 Million |
| Earnings Before Tax Margin | -0.12 | -1.02 | -0.78 | 0.00 | -0.03 | 0.06 |
| Breakdown | 2024 FY | 2024 Q4 | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 388.39 Million | 200.47 Million | 187.92 Million | 82.42 Million | 183.58 Million | 101.16 Million |
| Cost of Revenue | 229.28 Million | 87.48 Million | 113.6 Million | 38.71 Million | 156.74 Million | 118.02 Million |
| Gross Profit | 159.11 Million | 112.99 Million | 74.32 Million | 43.7 Million | 26.83 Million | -16.86 Million |
| Operating Expenses | 236.95 Million | 120.25 Million | 113.15 Million | 107.88 Million | 213.28 Million | 105.39 Million |
| Selling, General and Administrative Expenses | - | 109.6 Million | 102.91 Million | 100.53 Million | - | 97.01 Million |
| Research and Development Expenses | - | 10.64 Million | 10.24 Million | 7.35 Million | - | 8.37 Million |
| Other Expenses | - | - | - | - | 12.62 Million | - |
| Cost and Expenses | 466.23 Million | 207.73 Million | 226.76 Million | 146.6 Million | 370.03 Million | 223.42 Million |
| Operating Income | -77.83 Million | -7.25 Million | -38.83 Million | -64.18 Million | -186.44 Million | -122.26 Million |
| Interest Expense | 4.7 Million | 2.4 Million | 2.29 Million | 3.58 Million | 10.45 Million | 6.86 Million |
| Income Tax Expense | -21.46 Million | 17.15 Million | -4.31 Million | 85.1 Million | 47.74 Million | -37.36 Million |
| Earnings before Tax | -190.08 Million | -115.22 Million | -74.86 Million | -103.16 Million | -269.69 Million | -166.53 Million |
| Net Income | -174.23 Million | -103.68 Million | -70.55 Million | -171.84 Million | -316.41 Million | -144.57 Million |
| Earnings Per Share Basic | - | -1.25 | -0.87 | -2.06 | - | -1.64 |
| Earnings Per Share Diluted | - | -1.31 | -0.87 | -2.06 | - | -1.64 |
| Weighted Average Shares Outstanding | 79.62 Million | 83.24 Million | 81.24 Million | 83.42 Million | 81.24 Million | 88.24 Million |
| Weighted Average Shares Outstanding (Diluted) | 79.62 Million | 78.88 Million | 81.24 Million | 83.42 Million | 81.24 Million | 88.24 Million |
| Gross Margin | 0.41 | 0.56 | 0.40 | 0.53 | 0.15 | -0.17 |
| EBIT Margin | - | 0.12 | -0.02 | -0.34 | - | -0.92 |
| Profit Margin | -0.45 | -0.52 | -0.38 | -2.08 | -1.72 | -1.43 |
| EBITDA | - | 23.36 Million | -2.95 Million | -27.91 Million | - | -93.09 Million |
| Earnings Before Tax Margin | -0.20 | -0.04 | -0.21 | -0.78 | -1.02 | -1.21 |
7106
ME8U
GIFLF
DVHGF
3379
A1M